![](/images/graphics-bg.png)
Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure
Joint Authors
Poglajen, Gregor
Ksela, Jus
Frljak, Sabina
Zemljic, Gregor
Boznar Alic, Elizabeta
Cerar, Andraz
Vrtovec, Bojan
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-09
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Galectin-3 plasma levels (gal-3) were shown to correlate with the scar burden in chronic heart failure (CHF) setting.
As scar burden predicts response to stem cell therapy, we sought to explore a correlation between gal-3 and response to CD34+ cell transplantation in patients with CHF.
Methods.
We performed a post hoc analysis of patients, enrolled in 2 prospective trials investigating the clinical effects of CD34+ cell therapy in patients with ischemic cardiomyopathy (ICMP) and nonischemic dilated cardiomyopathy (DCMP).
CD34+ cells were mobilized by G-CSF, collected via apheresis, and injected transendocardially using NOGA system.
Patients were followed for 3 months and demographic, echocardiographic, and biochemical parameters and gal-3 were analyzed at baseline and at follow-up.
Response to cell therapy was defined as an LVEF increase of ≥5%.
Results.
61 patients were included in the analysis.
The mean age of patients was 52 years and 83% were male.
DCMP and ICMP were present in 69% and 31% of patients, respectively.
The average serum creatinine was 86±23 μmol/L, NT-proBNP 1132 (IQR 350-2279) pg/mL, and LVEF 30±6%.
Gal-3 at baseline and at 3 months did not differ significantly (13.4±5.5 ng/mL vs.
13.1±5.8 ng/mL; p=0.72), and there were no differences in baseline gal-3 with respect to heart failure etiology (15.1±7.2 ng/mL in ICMP vs.
12.7±4.3 ng/mL in DCMP; p=0.12).
Comparing responders (N=49) to nonresponders (N=18), we found no differences in baseline gal-3 (13.6±5.7 ng/mL vs.
13.2±4.9 ng/mL; p=0.80).
However, responders had significantly lower gal-3 at 3-month follow-up (12.1±4.0 ng/mL vs.
15.7±8.4 ng/mL; p<0.05).
Also, responders demonstrated a significant decrease in gal-3 over 3 months, while in nonresponders, an increase in gal-3 occurred (−1.5±5.4 ng/mL vs.
+2.7±4.3 ng/mL; p=0.01).
Conclusions.
In patients with chronic heart failure undergoing CD34+ cell therapy, a decrease in galectin-3 plasma levels is associated with beneficial response to this treatment modality.
Further prospective data is warranted to confirm our findings and to deepen our understanding of the role of gal-3 in the field of stem cell therapy.
American Psychological Association (APA)
Poglajen, Gregor& Ksela, Jus& Frljak, Sabina& Zemljic, Gregor& Boznar Alic, Elizabeta& Cerar, Andraz…[et al.]. 2019. Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure. Disease Markers،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1147901
Modern Language Association (MLA)
Poglajen, Gregor…[et al.]. Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure. Disease Markers No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1147901
American Medical Association (AMA)
Poglajen, Gregor& Ksela, Jus& Frljak, Sabina& Zemljic, Gregor& Boznar Alic, Elizabeta& Cerar, Andraz…[et al.]. Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1147901
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147901